Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: Results of a ten-year prospective study

Journal of Thoracic and Cardiovascular Surgery

Volumn 125, Issue 5, 2003, Pages 1121-1131

  Casson, Alan G ^a,c   Evans, Susan C ^a   Gillis, Amy ^a   Porter, Geoffrey A ^a   Veugelers, Paul ^a   Darnton, S Jane ^a   Guernsey, Duane L ^a   Hainaut, Pierre ^b   Swisher, Stephen G ^d   Casson, ^d   Mentzer, Steven J ^d   Waddell, Thomas K ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; DNA REPAIR; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; ESOPHAGUS RESECTION; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0037674951     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2003.176     Document Type: Article

References (68)

1. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-53.
2. Powell J, McConkey CC. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev. 1992;1:265-9.
3. Zhang ZF, Kurtz RC, Sun M, Karpeh M, Yu GP, Gargon N, et al. Adenocarcinomas of the esophagus and gastric cardia: Medical conditions, tobacco, alcohol, and socioeconomic factors. Cancer Epidemiol Biomarkers Prev. 1996;5:761-8.
4. Gammon MD, Schoenberg JB, Ahsan H, Risch HA, Vaughan TL, Chow WH, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1997;89:1277-84.
5. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-31.
6. Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:1055-62.
7. Montesano R, Hollstein M, Hainaut P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer (Pred Oncol). 1996;69:225-35.
8. Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol. 1999;154: 965-73.
9. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg. 2001;233:322-37.
10. Chen X, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis. 2001;22:1119-29.
11. Prives C, Hall PA. The p53 pathway. J Pathol. 1999;187:112-26.
12. Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, et al. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualization tools. Nucleic Acids Res. 1998;26:205-13.
13. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. Oncogene activation in esophageal cancer. J Thorac Cardiovasc Surg. 1991;102:707-10.
14. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res. 1991;51:4495-9.
15. Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu S, et al p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res. 1992;52:6092-7.
16. Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology. 1994;106:1589-95.
17. Hamelin R, Flejou JF, Muzeau F, Potet F, Laurent-Puig P, Fekete F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology. 1994;107:102-18.
18. Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Russell SE. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res. 1995;55:3406-11.
19. WAF1/CIP1/SDI1 gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol. 1996;27:1211-20.
20. Schneider PM, Casson AG, Levin B, Garewal HS, Hoelscher AH, Becker K, et al. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of 98 cases. J Thorac Cardiovasc Surg. 1996;111:323-33.
21. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer. 1994;74:2218-23.
22. Jones DR, Davidson AG, Summers CL, Murray GF, Quinlan DC. Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Ann Thorac Surg. 1994;57:598-603.
23. Rice TW, Goldblum JR, Falk GW, Tubbs RR, Kirby TJ, Casey G. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. J Thorac Cardiovasc Surg. 1994;108:1132-7.
24. Vijeyasingam R, Darnton SJ, Jenner K, Allen CA, Billingham C, Matthews HR. Expression of p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance. Br J Surg. 1994;81:1623-6.
25. Sauter ER, Keller SM, Erner SM. p53 correlates with improved survival in patients with esophageal adenocarcinoma. J Surg Oncol. 1995;58:269-73.
26. Casson AG, Kerkvliet N, O'Malley F. Prognostic value of p53 protein in esophageal adenocarcinoma. J Surg Oncol. 1995;60:5-11.
27. Monges GM, Seitz JF, Giovannini MF, Gouvernet JM, Torrente MA, Hassoun JA. Prognostic value of p53 protein expression in squamous cell carcinoma of the esophagus. Cancer Detect Prev. 1996;20:63-7.
28. Uchino S, Saito T, Inomata M, Osawa N, Chikuba K, Etoh K, et al. Prognostic significance of the p53 mutation in esophageal cancer. Jpn J Clin Oncol. 1996;26:287-92.
29. Ribeiro U, Finkelstein SD, Safatle-Riberio AV, Landreneau RJ, Clarke MR, Bakker A, et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer. 1998;83:7-18.
30. Krasna MJ, Mao YS, Sonett JR, Tamura G, Jones R, Suntharalingam M, et al. p53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients. Ann Thorac Surg. 1999; 68:2021-5.
31. Schneider PM, Stoeltzing O, Roth JA, Hoelscher AH, Wegerer S, Mizumoto S, et al. p53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Clin Cancer Res. 2000;6:3153-8.
32. Aloia TA, Harpole DH, Reed CE, Allegra C, Moore MB, Herndon JE, et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg. 2001;72:859-66.
33. Casson AG, Tammemagi M, Eskandarian S, Redston M, McLaughlin J, Ozcelik H. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. J Clin Pathol: Mol Pathol 1998;51:71-9.
34. Casson AG, Darnton SJ, Subramanian S, Hiller L. What is the optimum distal resection margin for esophageal carcinoma? Ann Thorac Surg. 2000;69:205-9.
35. Casson AG, Rusch VW, Ginsberg RJ, Zankowicz N, Finley RJ. Lymph node mapping of esophageal cancer. Ann Thorac Surg. 1994; 58:1569-70.
36. Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. 5th ed. New York: Wiley-Liss; 1997. p. 54-7.
37. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagastric junction. Br J Surg. 1998;85:1457-9.
38. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304-11.
39. Zahn Q, Carrier F, Fornace AJ. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol. 1993;13: 4242-50.
40. Tishler RB, Calderwood SK, Coleman CN, Price BD. Increases in sequence specific DNA binding by p53 following heat treatment with chemotherapeutic and DNA damaging agents. Cancer Res. 1993;53: 2212-6.
41. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-31.
42. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem. 1998;273:1-4.
43. Martin AC, Facchiano AM, Cuff AL, Hernandez-Boussard T, Oliver M, Hainaut P, et al. Integrating mutation data and structural analysis of the TP tumor-suppressor protein. Hum Mutat. 2002;19:149-64.
44. Riou G, Le MG, Travagli JP, Levine AJ, Moll UM. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst. 1993;85:1765-7.
45. Moll UM, La Quaglia M, Benard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A. 1995;92:4407-11.
46. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996;88:1442-55.
47. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci. 1999;54:64-75.
48. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, et al. p53 protein accumulation and p53 mutation in esophageal carcinoma: a molecular and immunohistochemical study with clinicopathologic correlation. Cancer. 1997;79:425-32.
49. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456-66.
50. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125:605-13.
51. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054-61.
52. Steup WH, De Leyn P, Deneffe G, Van Raemdonck D, Coosemans W, Lerut T. Tumors of the esophagogastric junction: long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg. 1996;111:85-95.
53. Ellis FH, Heatley GJ, Krasna MJ, Williamson WA, Balogh K. Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg. 1997;113:836-48.
54. Visbal AL, Allen MS, Miller DL, Deschamps C, Trastek VF, Pairolero PC. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg. 2001;71:1803-8.
55. Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred E, et al. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg. 2001;72:1918-25.
56. van Sandick JW, van Lanschot JB, ten Kate FJ, Tijssen JG, Obertop H. Indicators of prognosis after transhiatal esophageal resection without thoracotomy for cancer. J Am Coll Surg. 2002;194:28-36.
57. Taniere P, Martel-Planche G, Maurici D, Lombard-Bohas C, Scoazec JY, Montesano R, et al. Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. Am J Pathol. 2001;158:33-40.
58. Wynford-Thomas D. p53 in tumor pathology: can we trust immunocytochemistry? J Pathol. 1992;166:329-30.
59. Elledge RM. Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick? J Natl Cancer Inst. 1996;88:141-3.
60. Hainaut P, Vahakangas K. p53 as a sensor of carcinogenic exposures: mechanisms of p53 protein induction and lessons from p53 gene mutations. Pathol Biol. 1997;45:833-44.
61. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81-137.
62. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A. 1992;89:7262-6.
63. Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, et al. p53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996;88:519-29.
64. Dalquen P, Sauter G, Torhorst J, Schultheiss E, Jordan P, Lehmann S, et al. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol. 1996;178:53-8.
65. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Harrington AM, et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst. 1999;91:86-8.
66. Selaru FM, Zou T, Xu Y, Shustova V, Yin J, Mori Y, et al. Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene. 2002;21:475-8.
67. Casson AG. Role of molecular biology in the follow-up of patients who have Barrett's esophagus. Chest Surg Clin North Am. 2002;12: 93-111.
68. O'Shaughnessy JA, Keloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res. 2002;8:314-46